1. Introduction {#s0005}
===============

Since December 2019, the rapid propagation of a novel coronavirus (SARS-CoV-2) has broken out in China, and SARS-CoV-2 causes a novel pneumonia named COVID-19 [@b0005]. SARS-CoV-2 is a β-coronavirus with a genome highly homologous to bats, which probably originated from wild animals [@b0010]. Interpersonal transmission is the main cause of infection [@b0015]. The World Health Organization (WHO) has declared it as a public health emergency of international concern [@b0020]. As of May 3, 2020, a total of 3,405,914 cases were confirmed and 240,573 cases died globally [@b0025]. The clinical features of severe COVID-19 are similar to those of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). It can cause acute respiratory distress syndrome (ARDS), acute heart injury, and even death. Its main clinical features are fever, cough and sore throat. According to the clinical classification method, the patients were divided into four types: ordinary type, mild type, severe type and critically ill type according to the severity of the disease [@b0030], [@b0035]. In addition, the correlation between specific laboratory diagnosis and disease severity deserves attention. Several studies have reported different laboratory findings at the beginning of the outbreak of COVID-19 [@b0040], [@b0045], [@b0050]. The purpose of this survey is to reveal the characteristics of laboratory findings of COVID-19 through the included articles, especially the changes of severe and critically ill patients, so as to provide more information for COVID-19 \'s diagnosis.

2. Methods {#s0010}
==========

2.1. Literature search and selection {#s0015}
------------------------------------

PubMed and Web of Science were used to search for related articles. The key words are "2019-nCoV" "COVID-19" "SARS-CoV-2" "clinical characteristics" and "laboratory findings". To ensure the comprehensiveness and accuracy of the study, we also consulted the references of the included literature. The searches were performed three times to identify articles published before April 27, 2020. Then we screen the articles according to the abstract, eliminate the articles that obviously do not meet the inclusion criteria, and then read the full text for re-screening. Articles that provided values of laboratory indicators for severe and non-severe patients, including blood routine, inflammatory factors, biochemical and immune-related indexes were included. Pre-printed articles are also included. Articles published repeatedly, translated articles, studies did not include the laboratory indicators needed for *meta*-analysis; research data were missing were excluded. In addition, conference summaries, reviews and *meta*-analysis were excluded.

2.2. Analysis content {#s0020}
---------------------

Statistically analyzed the data related to laboratory indexes (blood routine, inflammatory markers, biochemical detection indexes, blood coagulation function and immune indexes) to compare the differences between severe and non-severe patients and summarize indicators with statistical significance and clinical value. These laboratory indicators were usually showed as the mean and standard deviation, but sometimes were median and interquartile range (IQR). The sample mean was estimated by Luo et al.\'s method [@b0055] and variance by Wan et al.\'s [@b0060] from the sample size, median and IQR. For these laboratory indexes, the inverse variance method for pooling was used to calculate the overall mean from studies reporting a single. The I^2^ statistic is a test used to quantify heterogeneity and values of I^2^ \> 50% indicated that heterogeneity existed. When statistical heterogeneity was identified, the random effects model will be used. The meta package (ver 4.11--0; <https://cran.r-project.org/>) was used to conduct the overall mean. In addition, we analyzed the correlation and regularity of diverse laboratory indexes in patients with COVID-19 to find the considerable advantages of combined analysis in the diagnosis and treatment of patients\' condition.

2.3. Risk of bias assessment {#s0025}
----------------------------

We will apply the following criteria to assess the risk of bias for each included study. 1. A clear purpose of the study; 2. Including continuous patients; 3. Expected collection of data; 4. The end point adapted to the research goal; 5. A fair assessment of the end point of the study; 6. A follow-up period commensurate with the objectives of the study; 7. Comprehensive laboratory indicators; 8. Sufficient numbers of patients. The project score is 0 (not reported), 1 (reported but insufficient), or 2 (reported and sufficient). The global ideal score for non-comparative studies is 16. In addition, we will draft funnel-plots for laboratory indicators with significant differences between severe and non-severe patients with COVID-19 if there are sufficient included studies (at least 10) and observe the symmetry of the funnel-plots to judge the publication bias.

3. Results {#s0030}
==========

3.1. Characteristics of included studies {#s0035}
----------------------------------------

The process of study selection is displayed in [Fig. 1](#f0005){ref-type="fig"} . A total of 715 publications were retrieved, including 645 articles on PubMed, 70 articles on Web of Science. Among these studies, 65 records were excluded due to duplication of records/titles. 615 were removed because they did not meet the inclusion criteria based on title and/or abstract. Finally, we obtained the laboratory test results of 35 articles describing 5912 COVID-19 confirmed patients (up to May 2020). The basic characteristics of the articles included in the study are shown in [Table 1](#t0005){ref-type="table"} .Fig. 1Flow diagram for selection of studies.Table 1Summary the characteristics of 35 studies that described the risk factors with COVID-19 patients.**AuthorJournalYearCountry/ regionNumber of total patientsNumber of non-severe patientsNumber of severe patientsAge, median (IQI) or mean (SD)**Qin C [@b0065]Clin. Infect. Dis.2020Shangha, China45216628658 (47--67)Chen X [@b0370]Clin. Infect. Dis.2020Wuhan, China48212764.6 ± 18.1Wang R [@b0375]Int. J. Infect. Dis.2020Anhui, China1251002538.8 ± 13.8Gao Y [@b0340]J. Med. Virol.2020Anhui, China432815Zheng YL [@b0085]J. Clin. Virol.2020Chengdu, China99673249.4 ± 18.45Ma J [@b0075]J. Infect.2020Wuhan, China37172062 (59--70)Wang DL [@b0090]Lancet2020Jiangsu, China6205675344.4 ± 17.2Liu W [@b0280]Chin. Med. J.2020Wuhan, China78671138 (33--57)Yang AP [@b0380]Int. Immunopharmacol.2020China93692446.4 ± 17.6Li KH [@b0385]Invest Radiol2020Chongqing, China83582545.5 ± 12.3Zhang JJ [@b0310]Allergy2020Wuhan, China140825857 (25--87)Huang CL [@b0050]Lancet2020Wuhan, China41281349 (41--58)Wang DW [@b0320]JAMA2020Wuhan, China1381023656 (42--68)Liu M [@b0070]Zhonghua Jie He He Hu Xi Za Zhi2020Wuhan, China3026435 ± 8Mo PZ [@b0390]Clin. Infect. Dis.2020Wuhan, China155708554 (42--66)Peng YD [@b0395]Zhonghua Xin Xue Guan Bing Za Zhi2020Shanghai, China112961662 (55--67)Feng Y [@b0400]Am. J. Respir. Crit. Care Med.2020China47635212453 (40--64)Cai QX [@b0405]Allergy2020Shenzhen, China2982405847.5 (33--61)Li H [@b0410]J. Infect.2020Wuhan, China132607262 ± 12.7Zheng F [@b0415]Eur Rev Med Pharmacol Sci2020Hunan, China1611313045 (33.5--57)Wang KK [@b0420]Lancet2020Hong Kong, China231310Guan W [@b0425]New Engl J Med2020Wuhan, China109992617347 (35--58)Gong J [@b0430]Clin. Infect. Dis.2020Wuhan and Guangdong, China1891612849 (35--63)Lei SQ [@b0435]E Clin Med2020China34191555 (43--63)Deng Q [@b0440]Int. J. Cardiol.2020Wuhan, China112456765 (49--70)Mao L [@b0445]JAMA Neurol.2020Wuhan, China2141268852.7 ± 15.5Du RH [@b0450]Ann. Am. Thorac. Soc.2020Wuhan, China109585170.7 ± 10.9Xie HS [@b0455]Liver Int.2020Wuhan, China79512860 (48--66)Wu J [@b0460]J. Intern. Med.2020China2801978343 ± 19Chen G [@b0465]J. Clin. Investig.2020Wuhan, China21101156 (50--65)Wan S [@b0470]J. Med. Virol.2020Chongqing, China135954047 (36--55)Pan HQ [@b0210]Lancet Infect. Dis.2020Wuhan, China2211665555 (39--66.5)Bo XU [@b0080]J. Infect.2020Wuhan, China1878010762 (48.5--71)GQQ [@b0475]Int. J. Med.2020Zhejiang, China9182950 (36.5--57)Lo LI [@b0480]Int. J. Biol. Sci.2020Macau, China106454 (27--64)

Among these articles, 34 articles described the results of blood routine and infection-related biomarkers, 26 articles described the results of biochemical tests, 23 articles provided test results for blood coagulation and 5 articles described the results of immunoassay. A total of 5,912 patients (mean age:54.80; 95%CI (52.50--57.20)), including 4337 non-severe patients (mean age:48.50; 95%CI (45.70--51.30)) and 1663 severe patients (mean age:61.00; 95%CI (59.10--62.90)). More than half of them were male (3072/5912(51.96%)). 2531 of these patients with underlying disease, including hypertension, diabetes, cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease and liver disease, Malignant tumors and patients with low immunity.

3.2. Analysis of laboratory indicators {#s0040}
--------------------------------------

Based on the comprehensive collation of the laboratory data provided in the selected 35 articles, the average value and variation range of various indexes of total patients, non-severe patients and severe patients were obtained and shown in [Table 3](#t0015){ref-type="table"} . In addition, the Funnel plot of important laboratory indicators are shown in [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"} .Table 2The quality assessment of included studies.**Author12345678Score**Qin C [@b0065]2222202214Chen X [@b0370]2222201112Wang R [@b0375]2.222222216Gao Y [@b0340]2222202113Zheng YL [@b0085]2222222115Ma J [@b0075]2222202113Wang DL [@b0090]2222222216Liu W [@b0280]2222202113Yang AP [@b0380]2222211113Li KH [@b0385]2222202113Zhang JJ [@b0310]2222202214Huang CL [@b0050]2222202113Wang DW [@b0320]2222212215Liu M [@b0070]2222202113Mo PZ [@b0390]2222212215Peng YD [@b0395]2222222115Feng Y [@b0400]2222202214Cai QX [@b0405]2222222216Li H [@b0410]2222221215Zheng F [@b0415]2222202214Wang KK [@b0420]2222222115Guan W [@b0425]2222222216Gong J [@b0430]2222222216Lei SQ [@b0435]2222222115Deng Q [@b0440]2222221215Mao L [@b0445]2222201213Du RH [@b0450]2222222216Xie HS [@b0455]2222202113Wu J [@b0460]2222202214Chen G [@b0465]2222201112Wan S [@b0470]2222212215Pan HQ [@b0210]2222212215Bo XU [@b0080]2222222216GQQ [@b0475]2222202113Lo LI [@b0480]2222221114[^2]Table3Results of Laboratory findings of severe and non-severe patients infected with COVID-19.**VariablesClassificationNumber of articles includedNumber of patients includedMean (95% CI)P-valueBlood routine**WBC×10^9^ /lNon-severe patients3442365.07 (4.90, 5.24)\<0.01Severe patients17036.06 (5.67, 6.46)All patients59395.39 (5.22, 5.55)Neutrophils×10^9^ /lNon-severe patients2930053.71 (3.36, 4.06)\<0.01Severe patients13684.94 (4.30, 5.58)All patients43734.22 (3.94, 4.51)Lymphocytes×10^9^ /lNon-severe patients3442281.15 (1.08, 1.22)\<0.01Severe patients17030.80 (0.75, 0.84)All patients59310.98 (0.92, 1.04)Eosinophil×10^9^ /lNon-severe patients510350.04 (0.03, 0.05)0.003Severe patients4510.02 (0.01, 0.02)All patients14860.03 (0.02, 0.04)Monocyte×10^9^ /lNon-severe patients1313970.41 (0.40, 0.42)0.086Severe patients7000.38 (0.35, 0.41)All patients20970.40 (0.39, 0.42)PLT×10^9^ /lNon-severe patients203068184.19 (178.04, 190.33)0.340Severe patients1019212.58 (154.63, 270.53)All patients4087201.44 (175.75, 227.12)Hb\
g/lNon-severe patients142652131.36 (128.33, 134.39)0.164Severe patients711126.73 (121.16, 132.30)All patients3363128.98 (126.17, 131.78)**Inflammation-related factors**ESR mm/60 minNon-severe patients8139028.16 (20.13, 36.2)0.111Severe patients69540.54 (27.61, 53.4)All patients208533.94 (28.10, 39.7)CRP mg/lNon-severe patients26293919.83 (16.67, 23.0)\<0.01Severe patients141560.91 (49.24, 72.5)All patients435436.99 (33.31, 40.67)PCT ng/mlNon-severe patients2223250.07 (0.05, 0.09)\<0.01Severe patients12220.14 (0.11, 0.17)All patients35470.10 (0.08, 0.12)**Blood biochemistry**ALT U/lNon-severe patients26276924.85 (22.69, 27.0)\<0.01Severe patients102733.78 (29.54, 38.0)All patients379628.31 (26.25, 30.3)AST U/lNon-severe patients26273126.24 (25.29, 28.18)\<0.01Severe patients101936.78 (33.69, 39.87)All patients375030.66 (29.19, 32.13)LDH U/lNon-severe patients192306224.20 (205.33, 243.07)\<0.01Severe patients811344.48 (307.08, 381.88)All patients3117271.82 (254.13, 289.52)CK U/lNon-severe patients17224177.69 (69.68, 85.70)\<0.01Severe patients849111.92 (98.24, 125.61)All patients309090.92 (83.54, 98.29)CK-MB U/lNon-severe patients913298.76 (4.74, 12.79)0.246Severe patients55012.26 (7.93, 16.58)All patients187910.51 (8.33, 12.70)Albumin g/lNon-severe patients1098539.41 (37.95, 40.87)\<0.01Severe patients43134.29 (32.79, 35.80)All patients141636.75 (35.17, 38.32)Creatinine μmol/lNon-severe patients25269666.97 (64.65, 69.28)\<0.01Severe patients100072.94 (69.23, 76.66)All patients369669.61 (67.57, 71.65)Urea mmol/lNon-severe patients1619294.36 (4.12, 4.59)\<0.01Severe patients7035.59 (5.39, 6.51)All patients26324.98 (4.72, 5.23)Total bilirubin mmol/lNon-severe patients14206510.38 (9.78, 10.99)0.017Severe patients56411.86 (10.81, 12.91)All patients262910.92 (10.39, 11.45)**Blood coagulation function**APTTsNon-severe patients12142233.49 (31.17, 35.82)0.724Severe patients40732.92 (30.78, 35.06)All patients182933.23 (31.59, 34.86)PT sNon-severe patients12138812.45 (11.98, 12.91)0.319Severe patients50412.80 (12.29, 13.30)All patients189212.63 (12.31, 12.94)D dimer mg/lNon-severe patients2325030.47 (0.40, 0.53)\<0.01Severe patients10431.29 (0.03, 0.54)All patients35460.61 (0.54, 0.67)**Lymphocyte subsets**CD4 T cells /μLNon-severe patients5475561.81 (485.46, 638.15)\<0.01Severe patients208266.79 (204.51, 329.07)All patients683407.03 (310.24, 503.83)CD8 T cells /μLNon-severe patients5475349.01 (292.61, 405.40)\<0.01Severe patients208174.61 (125.95, 223.27)All patients683266.65 (198.49, 334.81)**Cytokines**IL-1β pg/mlNon-severe patients22465.01 (4.96, 5.06)0.055Severe patients3935.11 (5.02, 5.20)All patients6395.06 (4.98, 5.15)IL-6 pg/mlNon-severe patients531213.22 (6.88, 19.57)0.027Severe patients45525.58 (16.69, 34.47)All patients76719.66 (13.44, 25.89)IL-10 pg/mlNon-severe patients22465.71 (5.51, 5.90)\<0.01Severe patients3938.87 (7.15, 10.59)All patients6397.23 (6.18, 8.28)[^3]Fig. 2Meta-analysis of lymphocytes.Fig. 3Meta-analysis of CRP.Fig. 4Meta-analysis of PCT.Fig. 5Meta-analysis of ALT.Fig. 6Meta-analysis of AST.Fig. 7Meta-analysis of LDH.Fig. 8Meta-analysis of D-dimer.Fig. 9Meta-analysis of CD4 T cells.Fig. 10Meta-analysis of IL-6.

### 3.2.1. Blood routine examination {#s0045}

Leukopenia was observed in 21.92% (363/1656) patients with lymphocytopenia in 29.02% (886/3053) patients. Elevated neutrophils were observed in 19.85% (81/408) patients. 14.73% (75/509) and 12.68% (78/615) patients were accompanied by a decrease in Hemoglobin and platelet count (PLT) respectively. Most importantly, there were several significant differences between severe patients and non-severe patients, including higher leukocyte (1.20-fold; 6.06 vs 5.07 × 10^9^/l; P \< 0.01) and neutrophil (1.33-fold; 4.94 vs 3.71 × 10^9^/l; P \< 0.01), lower lymphocyte (1.44-fold; 1.15 vs 0.80 × 10^9^/l; P \< 0.01), eosinophils (2.00-fold; 0.04 vs 0.02 × 10^9^/l; P = 0.03), monocytes (1.08-fold; 0.38 vs 0.41 × 10^9^/l; P = 0.041), PLT (1.15-fold; 212.58 vs 184.19 × 10^9^/l; P = 0.987) and hemoglobin (1.53-fold; 131.36vs 126.73 × 10^9^ g/l; P = 0.163).

### 3.2.2. Inflammatory biomarkers examination {#s0050}

Increased C-reactive protein (CRP) concentration appeared in 57.40% (1494/2603) patients, procalcitonin (PCT) increased in 12.20% (256/2099) patients, and 39.26% (117/298) patients had an increase in erythrocyte sedimentation rate (ESR). Moreover, higher levels of CRP (3.04-fold; 60.91 vs 19.83 mg/l; P \< 0.01), PCT (2.00-fold; 0.14vs 0.07 ng/ml; P \< 0.01) and ESR (1.44-fold; 40.54 vs 28.16 mm/60 min; P = 0.096) were observed in severe patients in comparison with non-severe patients.

### 3.2.3. Blood biochemical examination {#s0055}

#### 3.2.3.1. Cardiac markers examination {#s0060}

Our statistics showed that the related indexes of myocardial injury increased in different numbers of patients with COVID-19. (respectively creatine kinase (CK) (7.74% (157/2029)); aspartate aminotransferase (AST) (14.87% (388/2609)); lactate dehydrogenase (LDH) (24.50% (468/1910)). Several significant differences were noted between severe and non-severe patients, especially higher values of AST (1.40-fold; 36.78 vs 26.24 U/l; P \< 0.01), LDH (1.54-fold; 344.48 vs 224.20 U/l; P \< 0.01), CK (1.44-fold; 111.92 vs 77.69 U/l; P \< 0.01) and CK-MB (1.39-fold; 12.26 vs 8.76 U/l; P = 0.317).

#### 3.2.3.2. Liver function {#s0065}

The increase of alanine aminotransferase (ALT) (12.27% (296/2412)) and AST (14.87% (388/2609)) with COVID-19 has been observed. Moreover, the decrease of albumin (143/221 (64.70%)) was more common while the increase of total bilirubin (TBIL) was relatively rare in the majority of patients (109/1558 (6.70%)). Comparing with non-severe patients, higher ALT (1.34-fold; 33.78 vs 24.85 U/l; P \< 0.01), AST (1.40-fold; 36.78 vs 26.24 U/l; P \< 0.01), TBIL (1.14-fold; 11.86 vs 10.38 U/l; P = 0.024) and lower albumin (1.15-fold; 39.41vs 34.29 g/l; P \< 0.01) of severe patients has been worked out.

#### 3.2.3.3. Renal function {#s0070}

The increase of creatinine (2.41% (40/1659)) and urea (13.50% (47/348)) were observed among the included patients with COVID-19. Besides, albumin reduction (64.70% (143/221)) was very common. More importantly, higher levels of creatinine (1.09-fold;72.94 vs 66.97 μmol; P \< 0.01), urea (1.28-fold; 5.59 vs 4.36 mmol; P \< 0.01) and lower concentrations of albumin (1.15-fold; 39.41 vs 34.29 g/l; P \< 0.01) of severe patients were summed up in comparison with non-severe patients.

### 3.2.4. Blood coagulation function {#s0075}

Prothrombin time (PT) prolonged in 22.65% (53/234) patients and shortened in 10.68% (25/234) patients while activated partial thromboplastin time (APTT) prolonged in 21.79% (51/234) patients and shortened in 5.56% (13/234) patients. D dimer increased in 28.94% (534/1845) patients. Abnormal coagulation function is more obvious in severe patients, including shorter APTT (1.02-fold;33.49 vs 32.92 s; P = 0.804), increased D-dimer (2.74-fold; 1.29 vs 0.47 mg/l; P \< 0.01) and longer PT (1.03-fold; 12.80 vs 12.45 s; P = 0.407).

### 3.2.5. Immunological examination {#s0080}

#### 3.2.5.1. Antibody detection {#s0085}

The values of antibodies and complements in blood serum in Qin\'s [@b0065] study showed that immunoglobulins (IgA, IgG and IgM) and complement proteins (C3 and C4) of COVID-19 patients are within the normal range. Compared with the non-severe group, the IgM of the severe group was only slightly decreased, and there was no significant difference in other immunoglobulins and complement, which was consistent with the results of Feng\'s study [@b0070].

#### 3.2.5.2. Lymphocyte subsets {#s0090}

The total number of B cells, T cells and NK cells significantly decreased in patients with COVID-19 (852.9 /uL), and more evident in the severe cases (1.37-fold; 743.6 vs 1020.1 /uL; P = 0.032) compared to the non-severe group [@b0065]. Lower levels of CD4 T cells (2.10-fold; 561.81 vs 266.79 cell/μl; P \< 0.01), CD8 T cells (2.00-fold; 349.01 vs 174.61cell/μl; P \< 0.01) were summarized in severe patients comparing with non-severe patients from 5 articles [@b0070], [@b0075], [@b0080], [@b0085], [@b0090]. In addition, lower CD3 T cells (1.70-fold; 1070.23 vs 628.20 cell/μl; P \< 0.01) in severe patients was noted in Liu et al. [@b0090].

#### 3.2.5.3. Cytokine {#s0095}

Series of inflammatory cytokines were also increaseted in severe cases than the non-severe ones, including interleukin (IL)-1β (1.02-fold; 5.11 vs 5.01 pg/ml; P = 0.098), IL-6 (1.93-fold; 25.58 vs 13.22 pg/ml; P = 0.043), IL-10 (1.55-fold; 8.87 vs 5.71 pg/ml; P \< 0.01). In addition, Qin et al. found higher levels of IL-2R (1.14-fold; 757.0 vs 663.5 U/ml; P \< 0.01), IL-8 (1.34-fold; 18.4 vs 13.7 pg/ml; P \< 0.01) and TNF-α (1.04-fold; 8.7 vs 8.4 pg/ml; P = 0.037) in severe patients in comparison with non-severe patients [@b0065]. Studies also reported that GSCF, IP-10, MCP1and MIP1A in severe patients were higher [@b0050].

4. Quality assessment {#s0100}
=====================

Judging by the evaluation score, all of the included articles were classified as high quality and there was no considerable publication bias **(** [Table 2](#t0010){ref-type="table"} **).** The quality assessment graph and the reporting bias of important laboratory indicators are exhibited in [Supplementary materials](#s0135){ref-type="sec"}.

5. Reports on laboratory indicators of COVID-19 patients worldwide except China {#s0105}
===============================================================================

As the pandemic spreads to other countries and viral gene mutations, the characteristics of laboratory indicators of COVID-19 patients worldwide need to be grasped. Since only China has made a clear classification of the severity of patients with COVID-19, the definition of severe patients in countries expect China is simply summarized as staying in ICU. We decided to analyze the laboratory data of patients in representative articles about foreign countries to clarify the differences between foreign patients and Chinese patients with COVID-19.

In 21 critically ill patients with COVID-19 in Washington State, 67% and 38% of these patients had lymphopenia and abnormalities of liver function tests at admission respectively [@b0095]. Higher concentrations of IL-6 and D-dimer at admission were independently associated with in-hospital mortality, which has been confirmed in 1150 patients in New York [@b0100]. On a cohort of 300 COVID-19 patients from Italy, patients demonstrated lymphopenia in many cases [@b0105]. In another group of Italian cases, the frequency of granulocyte morphological anomalies has been highlighted, especially in patients with severe ARDS at admission [@b0110]. The values of leukocyte, IL-6, LDH, CK and D-dimer continued to increase in 50 COVID-19 patients with ARDS during hospitalization in a German report [@b0115]. About Singapore, lymphopenia was present in 39% patients (7/16) and an elevated CRP in 38% patients (6/16), while kidney function remained normal [@b0120]. Lower blood counts of leukocytes, platelets, neutrophils, lymphocytes, eosinophils, and basophils (all P \< 0.001) in COVID-19 patients were significant predictors of SARS-CoV-2 positive test [@b0125]. In addition, compared with less severe diseases, CRP is higher and the lymphocyte count is lower has been found in a study in Norway [@b0130].

Overall, we found that foreign patients have similarities to the changes in laboratory indicators of Chinese patients, typically including a decrease in leukocytes and lymphocytes and an increase in inflammation-related factors. The abnormality of blood coagulation, liver and kidney function and immune function also appeared in foreign patients, especially in severe and critically ill patients. However, due to differences in viral gene variation and detection time, the diversity in the laboratory indicators of patients around the world is inevitable, and more data required to confirm.

6. Discussion {#s0110}
=============

Facing the huge threat of COVID\--19 to human health, laboratory evaluation and early prediction of patients\' condition should be paid to more attention. At present, the characteristics of laboratory examination results of hospitalized patients were reported, but the discrepancies were observed between these reports due to the different proportions of severe patients in each study.

Among 5912 patients who underwent laboratory examinations on admission, lymphopenia was typical, which might be risk factors for disease progression of COVID-19 [@b0135]. The PLT-to-lymphocyte ratio (PLR) and the neutrophil/lymphocyte ratio (NLR) may provide new indexes for the monitoring the changes of patients with COVID-19 [@b0140], [@b0145], [@b0150]. The NLR was \> 5 in severe patients critically ill patients, proving that severe patients are more likely to develop leukocytosis and lymphocytopenia [@b0145]. Neutrophils and eosinophils may be used to predict the recovery probability [@b0155], [@b0160]. The decrease of hemoglobin and PLT were significantly associated with the severity of the disease [@b0165], [@b0170]. In addition, the combined parameter NLR&RDW-SD can help clinically to predict the severity of COVID-19 patients [@b0175]. In conclusion, blood routine examination is of great value in the diagnosis and prognosis of COVID-19.

High infection-related biomarkers (i.e. PCT, ESR, and CRP) have been observed in our study. CRP is a good predictor of adverse consequences and related to inflammation of tissues and organs [@b0180], [@b0185], [@b0190]. A simple death risk index (ACP) consisting of age and CRP was developed by Lu et al [@b0195], by which the short-term mortality associated with COVID-19 can be predicted. Higher serum hypersensitive C-reactive protein (hs-CRP) is an important marker of poor prognosis in COVID-19 patients and can be used to predict the risk of death in severe patients, which reflects the persistent state of inflammation [@b0200]. Increased PCT, SAA and ESR were identified as powerful factors to predict disease progression of patients with COVID-19 [@b0205], [@b0210], [@b0215], [@b0220]. In addition, the combined detection of IL-6, ESR and CRP improve the efficiency of predicting the development of patients\' condition [@b0225]. On account of the common co-infection in children, the increase of PCT is more obvious than that in adults, so it should be used as an important index for the detection of children [@b0230]. Thus, infection-related biomarkers are risk factors for disease progression.

In term of biochemical indicators, patients with organ dysfunction, (including ARDS, acute renal injury, heart injury, liver dysfunction, pneumothorax, etc.) are prone to exhibit abnormal results of blood biochemical examination [@b0235]. Increased serum N-terminal proB-type natriuretic peptide (NT-proBNP), cardiac troponin-I (cTnI), myoglobin and creatinine were related factors of critical COVID-19 with heart damage [@b0240], [@b0245]. Cardiac injury defined by the increase of hs-cTnI and D-dimer on admission and patients with high BNP is associated with a higher risk of mortality [@b0250], [@b0255], [@b0260]. LDH, AST/ALT ratio, TBIL could be identified as powerful predictive factors for early recognition of liver injury and were positively correlated with death risk of COVID-19 patients [@b0265], [@b0270], [@b0275]. Albumin, serum urea nitrogen and creatine were risk factor s for assessing kidney damage and disease progression [@b0275], [@b0280]. Many patients have abnormal urine analysis on admission, including proteinuria or hematuria, which indicates that urine analysis can better reveal the potential kidney damage of COVID-19 patients to reflect and predict the severity of the disease [@b0285], [@b0290]. In short, the cardiac biomarkers, liver and kidney function examination for severe and critically ill patients can evaluate the degree of extrapulmonary damage caused by complications.

Furthermore, the level of lactic acid, plasma angiotensin II, amylase and lipase can also be used as indicators to estimate the course of the disease [@b0245], [@b0295]. Plasma angiotensin II level linearly correlated with virus titer and the degree of lung injury was increased in one study [@b0245]. Other than the high expression of angiotensin-converting enzyme 2 (ACE2) in the pancreatic tissue of COVID-19 patients, the increase of serum amylase and lipase were found [@b0300]. In addition, the detection of electrolyte and blood glucose indexes is of great significance for patients with underlying diseases of electrolyte balance disorder and glucose metabolism disorder.

The changes in blood coagulation, especially disseminated intravascular coagulation (DIC), which is common in critical diseases, should also been paid enough attention [@b0305], [@b0310], [@b0315], [@b0320]. Severe patients may exhibit blood coagulation disorders, including increased D-dimer, prolonged PT and shortened APTT, which is consistent with reports [@b0310], [@b0315]. D-dimer is associated with the severity of COVID-19 [@b0325]. Fibrinogen can be significantly increased in the early stages of severe patients, but notably decreased in the later stages, this may be the reason why serious people are more likely to suffer from cerebrovascular disease [@b0330], [@b0335]. Bleeding and coagulation dysfunction and even DIC combined with COVID-19 is a process of dynamic change. Monitoring the blood coagulation function of patients is beneficial to the early diagnosis, prevention and treatment of the disease. In addition, The combined detection of IL-6 and D-dimer had important clinical value for early prediction of the severity of COVID-19 patients due to its high sensitivity and specificity [@b0340].

Our analysis showed that lower levels of CD4 and CD8 and higher levels of inflammatory cytokines (IL-1β, IL-6, IL-10) in severe patients, which made important impacts in predicting the state of the illness changes from mild to severe. The decrease of CD4 and CD8 in peripheral blood and the increase of IL-6 are the high-risk factors of cytokine release syndrome-like (CRSL) [@b0295], [@b0345], [@b0350]. CD3 + T cells, IP-10, MCP-3 and IL-1ra were also closely related to the severity and progression of COVID-19 [@b0270], [@b0355]. Diao et al. [@b0345] found that the number of T cells was negatively correlated with the concentration of serum IL-6, IL-10 and TNF-α. In addition, the immune response phenotype based on late IgG response can be used as a simple complementary tool to distinguish between severe and non-severe COVID-19 patients and to further predict their clinical outcomes [@b0360]. Overall, close monitoring of the T lymphocyte subsets and cytokines might provide valuable information on the patient's condition change during the treatment process [@b0365].

7. Limitations {#s0115}
==============

Although our analysis showed the characteristics of laboratory findings of COVID-19 patients, relatively few patients were included in the analysis. In addition, the recruited participants in our study were hospitalized before April 27, 2020 and more laboratory tests of COVID-19 patients should be investigated.

8. Conclusion {#s0120}
=============

Some certain laboratory inspections could predict the progress of the COVID-19 changes, especially, lymphocytes, CRP, PCT, ALT, AST, LDH, D-dimer, CD4 T cells and IL6, which provide valuable signals for preventing the deterioration of the disease.
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